Akums Drugs & Pharmaceuticals, a leading Indian contract development and manufacturing organization (CDMO), announced a landmark $200 million agreement with an undisclosed global pharmaceutical company to manufacture select oral liquid formulations for the European market.

Under the terms of the agreement, Akums will receive an upfront payment of $100 million to support product development and the approval of its manufacturing site by European regulatory authorities. Commercial supply of the formulations is scheduled to begin in 2027 and will continue through 2032, with the products marketed across multiple European countries by the pharma partner.

To fulfill the agreement, Akums will initiate the approval process for its oral liquid manufacturing site, aiming to secure both site and product dossier approvals by 2026. This will mark a significant expansion of Akums' European footprint, which already includes regulatory-approved facilities for injectables and oral solid dosage forms.

“This collaboration represents a pivotal milestone for Akums as we expand our offerings in the European market,” said Sandeep Jain, Managing Director of Akums. “Adding oral liquid formulations to our portfolio complements our existing European-approved capabilities for tablets, hard gelatin capsules, sachets, ampoules, vials, eye-drops, and dry powder injections.”

Akums' commitment to innovation and global regulatory compliance continues to position the company as a preferred partner for leading pharmaceutical companies worldwide. According to a recent McKinsey & Company report, India is projected to account for 8% to 10% of the global CDMO work share by 2033, further solidifying its role in the global pharmaceutical supply chain.

With this agreement, Akums reinforces its position as a key player in the CDMO landscape, leveraging its expertise to meet the evolving needs of the European pharmaceutical market.